Bibliografía del artículo
1. Hawkins SB, Bucklin M, Muzyk AJ. Quetiapine for the treatment of delirium. J Hosp Med 8:215-220, 2013.
2. Sanford M. Quetiapine extended release: adjunctive treatment in major depressive disorder. CNS Drugs 25:803-813, 2011.
3. Plosker GL. Quetiapine: a pharmacoeconomic review of its use in bipolar disorder. Pharmacoeconomics 30:611-631, 2012.
4. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, DeGaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relation- ship between plasma concentrations and clinical response. Clin Pharmacokinet 46(5):359-388, 2007.
5. Bui K, Earley W, Nyberg S. Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications. Curr Med Res Opin 29:813-825, 2013.
6. López-Muñoz F, Alamo C. Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front Psychiatry 12 (4):102, 2013.
7. Winter HR, Earley WR, Hamer- Maanson JE, Davis PC, Smith MA. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adol Psychopharmacol 18:81-98, 2008.
8. Prieto E, Micó JA, Meana JJ, Majadas S. Neurobiological bases of quetiapine antidepressant effect in the bipolar disorder. Actas Esp Psiquiatr 38(1):22-32, 2010.
9. Bakken GV, Rudberg I, Molden E, Refsum H, Hermann M. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit 33(2):222-226, 2011.
10. Fisher DS, Handley SA, Taylor D, Flanagan RJ. Measurement of quetiapine and four quetiapine metabolites in human plasma by LC- MS/MS. Biomed Chromatogr 26(9):1125-1132, 2012.
11. Bakken GV, Molden E, Knutsen K, Lunder N, Hermann M. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Drug Metab Dispos 40(9):1778-1784, 2012.
12. Altamura AC, Moliterno D, Paletta S, Buoli M, Dell'Osso B, Mauri MC, et al. Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observationa study. Clin Drug Investig 32:213-219, 2012.
13. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553-559, 2000.
14. Mundo E, Cattaneo E, Zanoni S, Altamura AC. The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder. Neuropsychiatr Dis Treat 2:139-148, 2006.
15. Rasmussen H, Ebdrup BH, Aggernaes B, Lublin H, Oranje B, Pinborg LH, et al. Norquetiapine and depressive symptoms in initially antipsychotic-naive first-episode schizophrenia. J Clin Psychopharmacol 33:266-269, 2013.
16. Björkholm C, Jardemark K, Marcus MM, Malmerfelt A, Nyberg S, Schilström B, et al. Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine. Eur Neuropsychopharmacol 23:709-720, 2013.
17. Silverstone PH, Lalies MD, Hudson AL. Quetiapine and buspirone both elevate cortical levels of noradrenaline and dopamine in vivo, but do not have synergistic effects. Front Psychiatry 3:82, 2012.
18. Sümegi A. Quetiapin in bipolar disorders. Neuropsychopharmacol Hung 10:281-291, 2008.
19. Stahl SM, Lee-Zimmerman C, Cartwright S, Morrissette DA. Serotonergic drugs for depression and beyond. Cur Drug Targets 14:578-585, 2013.
20. Cross A J, Widzowski D, Maciag C, Zacco A, Hudzik T, Liu J, Nyberg S, Wood MW. Quetiapine and its metabolite norquetiapine: translation from in vitro pharmacology to in vivo efficacy in rodent models. Br J Pharmacol 173(1):155-166, 2016.
21. Bortnick B, El-Khalili N, Banov M, Adson D, Datto C, Raines S, et al. Efficacy andtolerability of extended releasequetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 128(1-2):83-94, 2011.
22. Suppes T, Hirschfeld RM, Vieta E, Raines S, Paulsson B. Quetiapine for the treatment of bipolar II depression: Analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 9(3):198-211, 2008.
23. Riedel M, Musil R, Spellmann I, Seemüller F, Möller HJ. Quetiapine XR -a retard formulation in the treatment of schizophrenia. Eur PsychiatrRev 1:70-75, 2008.
24. Peuskens J. Themanagement of schizophrenia: focus on extended release quetiapine fumarate. Neuropsychiatr Dis Treat 7:549-564, 2011.
25. Rush AJ. Combining antidepressant medications: a good idea? Am J Psychiatry 167:241-243, 2010.
26. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 71:43-64, 2011.
27. Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 63 (12):1156-63, 2002.
28. Calabrese JR, Elhaj O, Gajwani P, Gao K. Clinical highlights in bipolar depression: focus on atypical antipsychotics. J Clin Psychiatry 66(Suppl 5):26-33, 2005.
29. Hirschfeld RM, Weisler RH, Raines SR, Macfadden W; BOLDER Study Group. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 67(3):355-362, 2006.
30. Milev R, Abraham G, Zaheer. Ad-on quetiapine for bipolar depression: a 12-month open-label trial. J Can J Psychiatry 51(8):523-530, 2006.
31. Endicott J, Rajagopalan K, Minkwitz M, Macfadden W; BOLDER Study Group. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol 22(1):29-37, 2007.
32. Baune BT, Caliskan S, Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol 22(1):1-9, 2007.
33. Del Bello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M, Bryan H, Vogel D, Sampang S, Delgado SV, Sorter M, Strakowski SM. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 11(5):483-493, 2009.
34. Vieta E, Valentí M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs 27(7):515-529, 2007.
35. Weisler RH, Calabrese JR, Thase ME, Arvekvist R, Stening G, Paulsson B, Suppes T. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 69(5):769-782, 2008.
36. Duffy A, Milin R, Grof P. Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability ofquetiapine. BMC Psychiatry 9:4, 2009.
37. Suppes T, Datto C, Minkwits M, Nordemham A, Walker C, Dato D. Effectiveness of the extended release formulation of quetiapine as monotherapy of the treatment of acute bipolar depression. J Affect Disor 121(1-2):106-15, 2010.
38. Young AH, Calabrese JR, Gustafsson U, Berk M, McElroy SL, Thase ME, Suppes T, Earley W. Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. Int J Bipol Disord 1:10, 2013.
39. Mc Elroy S, Hevey D. Relationship between adverse early experiences, stressors, psychosocial resources and wellbeing. Child Abuse Negl 38(1):65-75, 2014.
40. Ketter TA, Brooks JO 3rd, Hoblyn JC, Holland AA, Nam JY, Culver JL, Marsh WK, Bonner JC. Long-term effectiveness of quetiapine in bipolar disorder in a clinical setting. J Psychiatr Res 44(14):921-929, 2010.
41. Kim SJ, Lee YJ, Lee YJ, Cho SJ. Effect of quetiapine XR on depressive symptoms and sleep quality compared with lithium in patients with bipolar depression. J Affect Dis 157:33-40, 2014.
42. Spielmans GI, Berman I, Linardatos E, Rosenlicht RZ, Perry A, Tsai AC. Adjuntive atipycal antipsychotic treatment for Majior depressive disorder: a meta-analysis of depression, quality of life and safety outcomes. PoLS MED 10(3) e1001403, 2013.
43. Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Dis127(1-3):19-30, 2010.
44. Bandelow B, Bauer M, Vieta E, El-Khalili N, Gustafsson U, Earley WR, Eriksson H. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. World J Biol Psychiatry 15(2):155-66, 2014.
45. Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int Clin Psychopharmacology 27(1):27-39, 2012.